Comparison of urinary and serum CA 19-9 as markers of early stage urothelial carcinoma

International Braz J Urol

Volumn 39, Issue 5, 2013, Pages 631-638

  Roy, Suparna ^a   Dasgupta, Anindya ^a   Kar, Kaushik ^a  

^a CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

Author keywords

CA 19 9 Antigen; Odds Ratio; Tumor Markers, Biological

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLADDER TUMOR; BLOOD; CANCER GRADING; CANCER STAGING; CONFIDENCE INTERVAL; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; TRANSITIONAL CELL CARCINOMA; URINE;

AGED; CA-19-9 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; CONFIDENCE INTERVALS; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; REFERENCE VALUES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84891646490     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2013.05.04     Document Type: Article

References (22)

1. Vaidyanathan K, Vasudevan DM: Organ Specific Tumor Markers: What's New? Indian J Clin Biochem. 2012; 27: 110-20.
2. Taguchi A, Hanash SM: Unleashing the power of proteomics to develop blood-based cancer markers. Clin Chem. 2013; 59: 119-26.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-49.
4. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin. 2000; 50: 7-33.
5. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, et al.: Bladder Cancer Working Group report. Jpn J Clin Oncol. 2010; 40(Suppl 1): i57-64.
6. Rodríguez-Rubio F, Sanz G, Garrido S, Sánchez C, Estudillo F: Patient tolerance during outpatient flexible cystoscopy- -a prospective, randomized, double-blind studycomparing plain lubrication and lidocaine gel. Scand J Urol Nephrol. 2004; 38: 477-80.
7. Papanicolaou GN, Marshall VF: Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 1945; 101: 519-20.
8. Grossfeld GD, Litwin MS, Wolf JS Jr, Hricak H, Shuler CL, Agerter DC, et al.: Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrologyevaluation, and follow-up. Urology. 2001; 57: 604-10.
9. Nagao K, Itoh Y, Fujita K, Fujime M: Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes. Int J Urol. 2007; 14: 795-9.
10. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al.: Radioimmunometric assay for a monoclonal antibodydefined tumor marker, CA 19-9. Clin Chem. 1983; 29: 549-52.
11. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H: Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res. 1982; 42: 4820-3.
12. Fong ZV, Winter JM: Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012; 18: 530-8.
13. Bluvshtei'n GA, Lysenko VG, Zakharova NB, Kitaev IV: Tumor markers p53, sFAS, FASL, CEA and CA 19-9 in evaluating the effectiveness of surgical and pharmaco nutritionaltreatment of patients with gastric cancer. Eksp Klin Gastroenterol. 2012; 2: 41-9.
14. Ohshio G, Ogawa K, Kudo H, Yamabe H, Higuchi K, Nakashima Y, et al.: Immunohistochemical distribution of CA19-9 in normal and tumor tissues of the kidney. Urol Int. 1990; 45: 1-3.
15. Terracciano D, Mariano A, Macchia V, Di Carlo A: Analysis of glycoproteins in human colon cancers, normal tissues and in human colon carcinoma cells reactive withmonoclonal antibody NCL-19-9. Oncol Rep. 2005; 14: 719-22.
16. Aybek H, Aybek Z, Sinik Z, Demir S, Sancak B, Tuncay L: Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol. 2006; 13: 1380-4.
17. Parra JL, Kaplan S, Barkin JS: Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci. 2005; 50: 694-5.
18. Pal K, Roy S, Mondal SA, Chatterjee U, Tiwari P, Bera M: Urinary level of CA19-9 as a tumor marker in urothelial carcinoma of the bladder. Urol J. 2011; 8: 203-8.
19. Barone D, Onetto M, Conio M, Paganuzzi M, Saccomanno S, Aste H, et al.: CA 19-9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers. 1988; 3: 95-100.
20. Whelan P, Britton JP, Dowell AC: Three-year follow-up of bladder tumours found on screening. Br J Urol. 1993; 72: 893-6.
21. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE: Malignant urachal lesions. J Urol. 1984; 131: 1-8.
22. Schwalb DM, Herr HW, Fair WR: The management of clinically unconfirmed positive urinary cytology. J Urol. 1993; 150: 1751-6.